Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 641 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Embracing Bravery When You Have a Genetic Cancer Disease January 13, 2021 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Bringing a Piece of Home to the Hospital April 4, 2023 Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community November 13, 2021 Load more HOT NEWS Routes to a healthier shopping journey – how your supermarket environment... National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... 2023 ASCO Annual Meeting Research Round Up: New Research in Treating...
